Novo Nordisk stock skidded Tuesday after Eli Lilly's weight-loss drug outperformed Novo's rival medication in a first-of-its-kind study. The post Lilly's…
Risankizumab outperformed ustekinumab in rates of clinical remission at week 24 and rates of endoscopic remission at week 48, meeting both primary endpoints of the phase 3 trial.